Call for Abstract
13th World Conference on Neurology and Neuromuscular Disorders, will be organized around the theme “Explore the New Technologies and Methodologies in Neurology and Neuromuscular Disorders”
Neurology Conference 2018 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Neurology Conference 2018
Submit your abstract to any of the mentioned tracks.
Register now for the conference by choosing an appropriate package suitable to you.
Neuromuscular Disorders is a term that encompasses many diseases and ailments that impairs with the functioning of muscles. It affects the peripheral nervous system, which consists of all the motor and sensory nerves that connect the brain and spinal cord to the rest of the body. Dynamic muscle weakness is the predominant state of these disorders.
Example of NMD includes:
- Amyotrophic lateral sclerosis
- Multiple sclerosis
- Myasthenia gravis
- Spinal muscular atrophy
Myasthenia Gravis is an autoimmune disease that affects the neuromuscular junction. With a prevalence of 150-250 cases per 1 million, MG and its subgroups are the major disorders that affect neuromuscular junction.
Multiple Sclerosis is an inherited disorder. According to the estimation of Multiple Sclerosis Foundation, about 2.5 MN people around the world have MS. The ration of men with MS to women with the disease is 1 to 2. Amyotrophic lateral sclerosis is a progressive neurological disorder that affects the function of nerves and muscles. According to an estimation ALS is the cause of five in every 100, 000 deaths in people ages 20 or older
Spinal Muscular Atrophy is a fatal autosomal recessive disorder which affects 1 in 40 people that carries SMA gene. It causes progressive muscle wasting and paralysis.
- Track 1-1Multiple sclerosis
- Track 1-2Care Practice and Awareness
- Track 1-3Anterior,Central & Posterior Cord syndrome
- Track 1-4Spinal muscular atrophy
- Track 1-5Amyotrophic lateral sclerosis
- Track 1-6Muscular dystrophy
- Track 1-7Neuromuscular junction disorder
- Track 1-8Spasticy
- Track 1-9Spine muscular atropies
- Track 1-10Hyper reflexia
- Track 1-11Myasthenia gravis
- Track 1-12Therapeutic Targets & Mechanisms for Treatment
Peripheral Nerves usually describe the peripheral nervous system. PNS system consists of a motor and sensory nerves that connect the brain and spinal cord and the central nervous to the rest body. It controls the function of movement and motor coordination. The disorders related to the peripheral nerve described as PNS disorders that occur due to injury, trauma or compression. Compression of the nerve is due to the tumour mas or injury. Sometimes surgery is the only option when this nerve suffers injury or trauma. Physical trauma is a common cause of injury to peripheral nerves.
Peripheral Neuropathy is the common condition that affects 2.4% of the total population. Hence its prevalence increases to 8% with growing age.
Diabetic Sensorimotor Polyneuropathy, a polyneuropathy disease which may be present 66% of type 1 diabetic patients as compared to 59% in type 2 diabetic patients.
- Track 2-1Somatic nervous system
- Track 2-2Autonomic nervous system
- Track 2-3Peripheral neuropathy
- Track 2-4Nerve Block
- Track 2-5Nerve tumours
- Track 2-6Carpal tunnel syndrome
- Track 2-7Sarcoidosis
Child Neurology is a branch of medicine that deals with the diagnosis of neurological diseases infants, children and adolescents. It encompasses the diseases of PNS, CNS, Spinal Cord, brain and blood vessels that affects an individual in this age group. About 40% to 50% of the patients treated in a typical paediatric neurology practice have epilepsy, while 20% have developmental problems and remaining’s are suffering from headaches and some are treated for unusual conditions such as genetic diseases.
Some of the diseases diagnosed in paediatric neurology are:
- Childhood Epilepsy
- Neurodegenerative and Neurometabolic disorders
- Motor disorders
- Febrile seizures
- Headaches and migraine
- Genetic diseases of the nervous system
According to Global Business Intelligence Research report, the epilepsy therapeutic market value in major countries (US, France, Canada, Germany, Italy, Japan, and Spain) will increase at modest CAGR of 3.9%.
The epilepsy therapeutic market in 2012 is $3.4 billion which extended up to $4.5 billion by 2019.
In case of Epilepsy diseases, North America market is the most mature market, which is expected to reach with an estimated value of over USD 2,500 million by 2024.
Some of the key players in Epilepsy drug market are Sanofi S.A, Abbott Laboratories, Inc., Sunovion Pharmaceuticals, Inc., UCB Pharma Ltd., Johnson & Johnson, Novartis AG etc.
- Track 3-1Childhood Epilepsy
- Track 3-2Neurodegenerative and Neurometabolic disorders
- Track 3-3Motor disorders
- Track 3-4Febrile seizures
- Track 3-5Headaches and migraine
- Track 3-6Genetic diseases of the nervous system
Neuromodulation is a treatment for relieving the chronic pain. In this process small doses or weak electrical signals are used to alter the pain signals. This method is a life changing for individuals living with unmanageable chronic pain and/or movement disorders. This process affects all areas of the body were pain lingers.
There is a number of forms for Neuromodulation:
- Spinal Cord Stimulation (SCS)
- Peripheral Nerve Stimulation (PNS)
- Deep Brain Stimulation (DBS)
Neuromodulation is one of the best methods which have the ability to treat pain without relying on medications.
Around 60% patients show improvement in their lifestyle with chronic pain following implantation of peripheral nerve stimulators.
In clinical trials, after getting a treatment with Spinal Cord Stimulation (SCS), approximately 59% patients suffered from chronic pain reported excellent pain relief.
Deep Brain Stimulation (DBS) provides long term improvement in the quality of life to the patients suffering from Parkinson’s disease, essential tremor and dystonia.
- Track 4-1Spinal Cord Stimulation (SCS)
- Track 4-2Peripheral Nerve Stimulation (PNS)
- Track 4-3Deep Brain Stimulation (DBS)
Movement Disorders are a group of diseases of neurological conditions that affect the speed, quality, and ease of movement which may be voluntary or involuntary. More than 30 diseases are diagnosed as neurological movement disorders. Movement disorders are often induced by neurotic changes inside the brain. Regularly, the reason may not be known, despite the fact that heredity and environment factors having a role in some cases. The treatment includes medication, occupational and physical therapy and surgical procedures.
Types of Movement Disorders are:
- Essential Tremor
- Parkinson's Disease
- Atypical Parkinsonism
According to Epidemiology studies, The Ataxia prevalence is of around 10 per 100,000 populations and idiopathic ataxia likely outnumbers genetic cases.
Dystonia is a disorder of muscles that causes slow abnormal postures of the musculature that are uncontrolled by the patient. According to a report Global cervical dystonia market is expected to grow at a CAGR of 5% during the forecast period of 2017-2023.
Parkinson’s disease is common age related neurodegenerative disorder. An estimated 10 million people suffer from Parkinson's disease and expected to increase every year. A patient suffered from this disease spends around $2500 per year on the medications to aid in ease of life.
- Track 5-1Ataxia
- Track 5-2Dystonia
- Track 5-3Essential Tremors
- Track 5-4Atypical Parkinsonisms
Neurosurgery is the speciality concerned with the diagnosis and treatment of patients with injury or diseases of the brain, spinal column, spinal cord and peripheral nerves in all parts of the body. It is a sister discipline to neuromedicine which deals in the diagnosis and treatment of neurological diseases and complications using medications and non-surgical methods.
Some of the types of Neurosurgery are:
- Spine neurosurgery
- Plastic Neurosurgery
- Oncological neurosurgery
- Current neurosurgery methods
Neuroanaesthesia and surgery
Global Neurosurgical Devices Market is expected to grow at a CAGR around 9% during the forecast period.
Nearly 13.46% of the global population suffering from neurological disorders. Some of the most prevalent diseases are Epilepsy, Parkinson’s Diseases, Alzheimer diseases and Neuro-infections. Neurological disorders are the cause behind the 10% of death all over the world.
According to a report Global Neurosurgical Devices Market is expected to grow at a CAGR of 10.5% between the forecast periods of 2017-2023.
- Track 6-1Plastic Neurosurgery
- Track 6-2Post-surgical neuralgias
- Track 6-3Tumour and metastatis
- Track 6-4Oncological neurosurgery
- Track 6-5Spine neurosurgery
- Track 6-6Current neurosurgery methods
- Track 6-7Vascular Neurology
- Track 6-8Neuroanaesthesia and surgery
- Track 6-9Advancement in personalized medicine
Qualities influence the wiring and workings of the mind, which is the power of every one of our rides. It is eventually and exclusively the qualities that offer ascent to a specific kind of protein that might be useful or hurtful that mirrors the need of research in this specific field. 6000 and all the more rising hereditary issue represent a noteworthy partition of human sickness and conditions. Almost 4 percent of the around 4 million children conceived every year have a hereditary malady or significant birth imperfection. Around 15,000 Americans are analysed to have Huntington's illness (HD).Keeping the same in view the accompanying sub tracks are intended to illuminate the contemplations identified with Huntington's sickness (HD) and related hereditary issue.
Some of the Neurogenetics disorders are:
- Huntington disease
- Cancer genetics
- Gene defect and diseases
- Biochemical genetics
Neurological diseases give their impact to estimated 100 million Americans every year. The cost of Stroke and Dementia alone expected to figure more than $600 billion by 2030.
According to a report, estimated 5.5 million Americans are living with Alzheimer’s disease in 2017. Two-thirds of Americans with Alzheimer’s are women.
The Alzheimer's disease Therapeutics and Diagnostics Market reached at $6.71bn in the year 2016 and is expected to grow at a CAGR of 15.3% in the 2nd half of the forecasted period.
- Track 7-1Huntington disease
- Track 7-2Cancer genetics
- Track 7-3Gene defect and diseases
- Track 7-4Genome wide association studies
- Track 7-5Biochemical genetics
- Track 7-6Gene mutation and disease
- Track 7-7Genetic engineering and Gene sequencing
Neurodevelopment disorders are the disabilities or the group of disorders associated with the developmental deficits of the central nervous system. It shows up early in child’s development, affecting in many areas of life function and encompasses disorders of language and speech, movement, the special senses, learning, or other neurological functions. The symptoms and behaviours of neurodevelopment disorders changes as a child grows older. While some disorders are permanent. The diagnosis and treatment of these disorders are not know or difficult but medication and therapies with some home base programs are exist for the cure of these disorders.
Some of major neurodevelopment disorders are:
- Attention Deficit Hyperactivity Disorder (ADHD)
- Autism Spectrum Disorders (ASD)
- Cerebral palsy
- Expression disorder
- Impairments in vision and hearing
According to the reports of Persistence Market research ADHD therapeutics market is expected to expand at a CAGR of 6.2% during forecast period 2015 – 2024. The market segmentation based on the drug type, age group, distribution channel and region.
The Lisdexamfetamine Dimesylate drug type sub-segment is expected to grow at highest CAGR of 15.6% in value terms during the forecast period.
In USA, 11% of children between the age of 4 and 17 and of total 4.4% of adults suffered from the ADHD Diseases.
- Track 8-1Attention Deficit Hyperactivity Disorder (ADHD)
- Track 8-2Autism Spectrum Disorders (ASD)
- Track 8-3Intellectual disability
- Track 8-4Cerebral palsy
- Track 8-5Speech disorder (dislalia)
- Track 8-6Comprehension disorder
- Track 8-7Expression disorder
- Track 8-8Impairments in vision and hearing
Neurodegeneration or neuron demise is the dynamic loss of structure or capacity of neurons which incorporates disarranges like Alzheimer's illness, Parkinson's malady and so on. In the United States, close around 60,000 instances of Parkinson's illness are analysed every year. The third driving reason for death after tumour and coronary illness is Stroke, along these lines concentrating on the study of disease transmission of stroke and hazard factors. Stroke can be of various sorts.
Some of major neurodegenerative disorders are:
- Haemorrhage stroke and ischemic stroke
- Amyotrophic lateral sclerosis (ALS)
- Imaging, diagnosis and acute stroke management
The global Central Nervous System (CNS) therapeutic market size was worth USD 77.2 billion in 2016 and is anticipated to grow at a CAGR of 5.9% during the forecast period.
Global multiple sclerosis market is rapidly growing and it is expected to cross US$ 20 Billion by 2022.
- Track 9-1Epidemiology of Brain stroke
- Track 9-2Risk factors of Stroke
- Track 9-3Haemorrage stroke and ischemic stroke
- Track 9-4Amyotrophic lateral sclerosis (ALS)
- Track 9-5Imaging, diagnosis and acute stroke management
- Track 9-6Novel Insights for Parkinsons disease
Neuroimmunology is the branch that deals with the interaction of immune system with nervous system in the health and diseases such as the effect of autonomic nervous activity on the immune response (as multiple sclerosis). This diseases occurs when immune system “activated” by an infection or vaccine. In that case immune system damages the peripheral nerves, brain or spinal cord.
Some of examples of diseases in this category include:
- Multiple Sclerosis
- Optic neuritis
- Transverse myelitis
- Guillain-Barre Syndrome
- Chronic inflammatory demyelinating polyneuropathy
- Myasthenia Gravis
According to technavio report, the global acute ischemic stroke (AIS) therapeutics markets to grow at a CAGR of more than 2% of during the forecast period.
Global myasthenia gravis drugs market to grow at a CAGR of 13.16% during the forecast period 2017-2021.
- Track 10-1Multiple Sclerosis
- Track 10-2Optic neuritis
- Track 10-3Transverse myelitis
- Track 10-4Guillain-Barre Syndrome
- Track 10-5Chronic inflammatory demyelinating polyneuropathy
It expands the reviews on the sensory system and the endocrine framework which mirrors the reviews on hormonal reactions at the ganglions and their sources in cerebrospinal liquids pituitary organs.
It utilizes a Wide scope of neuroscience systems extending from sub-atomic science and hereditarily controlled rat models to electrophysiological, ontogenetic, morphological, cell imaging and entire creature ways to deal with get the certainties how the mind fortifying hormone levels and how hormones accordingly control cerebrum work.
Some of the track include in Neuro Endocrinology:
- Neuro Endocrine cells
- Adrenal glands
The global Huntington’s disease therapeutics market to grow at a CAGR of 14.75% during the period 2017-2021
- Track 11-1Neuro Endocrine cells
- Track 11-2Hypothalamus
- Track 11-3Neurohypophysis
- Track 11-4Adrenal glands
- Track 11-5Pituitary glands
Autonomic and Central issue may come about because of different issue that harm autonomic nerves or they may happen all alone. Dynamic autonomic disappointment normally gets to be evident in the 6th decade of life. The Working of the focal sensory system has turned out to be increasingly broad and more crucial as examination has progressed in analysing it. CNS issue can be either myelopathy or encephalopathy.
Some of the tracks include in CNS Disorders:
- Bipolar Disorder
- Neuropathic pain syndromes
- Accessory nerve disorder
- CNS disorder and structural defects
According to a report Central Nervous System (CNS) Disorders Therapeutics Market to grow at 5.59% CAGR during the period 2016-2020. And, is expected to reach $128.9 Billion.
Global mental health therapeutics revenue accounted for 48% share in 2016 and is expected to grow at a significant rate from 2016 to 2025.
- Track 12-1Bipolar Disorder
- Track 12-2Neuropathic pain syndromes
- Track 12-3Accessory nerve disorder
- Track 12-4CNS disorder and structural defects
- Track 12-5Facial nerve paralysis
- Track 12-6Meningitis
- Track 12-7Therapies for genetic disorders
Brain issues happens when Brain is harmed by Brain damage, illness, or wellbeing conditions. The three Brain chemicals noradrenaline, dopamine and serotonin are included in both real capacities and Brain.
There are 10 million individuals in the UK living with a neurological condition which significantly affects their lives. Basically stroke, dementia, cerebral pain, Brain damage and epilepsy are the neurological conditions endured in UK. It has been evaluated that the lifetime danger of creating Brain and other focal sensory system malignancy is 1 in 133 for men and 1 in 185 for ladies in the UK.
The objective of this session is to comprehend the Causes, Origin, Genesis and Source of different sorts of Brain issues. The reasons for Brain issues: Brain injury, Stroke, Viral contaminations, Tumour, Brain's electrical pathway and Genesis of Brain.
Some of the major brain disorders are:
- Brain Stroke
- Autism and Schizophrenia
- Neuropharmacology and Therapeutics
- Therapies for genetic disorders
The global brain monitoring devices market is expected to grow at a CAGR of 6.5% and 7.0% during the forecasting period 2017-2023 and is expected to touch the figure of $10,011.5 million by 2023.
- Track 13-1Brain Stroke
- Track 13-2Autism and Schizophrenia
- Track 13-3Neuropharmacology and Therapeutics
- Track 13-4Therapies for genetic disorders
It is the harm to the spinal cord that causes changes in its capacity, either transitory or lasting. These progressions convert into loss of muscle capacity, sensation, or autonomic capacity in parts of the body served by the spinal line beneath the level of the sore. Wounds can happen at any level of the spinal rope and can be named finished harm, an aggregate loss of sensation and muscle work, or inadequate, which means some apprehensive signs can go past the harmed range of the string.
Some of the major Spinal Injuries are:
- Duchenne Muscular Dystrophy
Spinal cord injuries affect over 40K people in the UK and around 270,000 in the US.
There are 12K new cases of spinal cord injury in the US each year.
According to a report, Global Slip Disc markets grow at the CAGR of ~5.4% during the forecast period and are expected to reach USD 11,011.3 million by 2023.
- Track 14-1Scoliosis
- Track 14-2Kyphosis
- Track 14-3Flatback syndrome
- Track 14-4Scheuermanas disease
- Track 14-5Duchenne Muscular Dystrophy
- Track 14-6Osteoporosis
Dementia is a decline in mental ability severe enough to interfere with day to day life. The most commonly occurring symptoms of dementia are decrease in ability to think and remember, emotional problems, problems with language, decrease in motivation. World Health Organisation’s list of top ten leading causes of deaths all over the world, Alzheimer’s and other dementias has 7th ranking. Dementia has overtaken as leading cause of death in England and Wales over heart diseases. Alzheimer’s is one of the major causes of death in the USA and it kills more than breast and prostate cancer combined. To solve problems of globally various dementia conferences were arranged to find cure for dementia society universally.
Sub sessions of the dementia are:
- Vascular Dementia
- Traumatic brain injury
- Diagnosis and Symptoms
- Imaging Techniques
- Geriatrics and Cognitive Disorder
According to Research and Markets report, the global dementia and movement disorder treatment market to grow at a CAGR of 4.48% during the period 2017-2021.
On estimation, 850, 000 people are living with dementia in the UK.
Globally, the people suffer from Dementia will increase from 46.8m in 2015 to 131.5m in 2050, a 281% increase
- Track 15-1Vascular Dementia
- Track 15-2Traumatic brain injury
- Track 15-3Diagnosis and Symptoms
- Track 15-4Imaging Techniques
- Track 15-5 Geriatrics and Cognitive Disorder
- Track 15-6Alzheimers clinical trials and studies
The underlying assessment of a patient with a recently analysed tumour of the sensory system is a basic stride toward proper administration and patient care. The most critical segments of the underlying assessment are an itemized history and an exhaustive examination. This procedure serves to distinguish the degree and nature of neurological shortfall, gives indicative insights, can help unveil a wellspring of metastasis, or may recognize a hereditary procedure connected with an essential focal sensory system tumour.
There is no doubt that the clinical administration of neuro-oncology patients is testing. In any case, on the off chance that we are to help patients and eventually make propels in treating these tumours, fastidious and humane care of patients with neurological malignancies are pivotal.
Lumbar cut (LP) and cerebrospinal fluid (CSF) examination are essential for the assessment of some essential tumours, metastatic conditions, and neurologic complexities of growth
Sub Sessions in Neuro-oncology are:
- Psycho Oncology
- Radiation therapy
- Neuropharmacology of cancer
- Inoperable brain tumor
According to the reports, the radiation Oncology market size is expected to reach USD 10.1 billion by 2025.
- Track 16-1Psycho Oncology
- Track 16-2Radiation therapy
- Track 16-3Neuropharmacology of cancer
- Track 16-4Glioblastoma survival rate
- Track 16-5Pediatric oncologist
- Track 16-6Inoperable brain tumor
- Track 16-7Craniopharyngioma
- Track 16-8Brain tumor
- Track 16-9Butterfly glioma
Parkinson’s sickness is a dynamic issue of the sensory system that influences development. It grows slowly, in some cases beginning with a scarcely detectable tremor in only one hand. However, while a tremor might be the most surely understood indication of Parkinson's infection, the turmoil likewise regularly causes solidness or moderating of development. In the early phases of Parkinson's illness, your face may indicate next to zero demeanours, or your arms may not swing when you walk. Your discourse may turn out to be delicate or slurred. Parkinson's malady indications compound as your condition advances after some time.
Sub sessions of the Parkinson’s Diseases:
- Neorocognitive Disorders
- Pathophysiology and Pharmacology
- Managing life with Parkinson’s disease
According to the WHO, the number of people with disability-adjusted life year due to Parkinson’s disease was 1.7 million globally in 2015.
According to European Parkinson’s Disease Association, the cost of treatment for this disease in Europe was estimated at US$ 12.6 Million in 2005 and is expected to double by 2030.
As per the European Brain Council around 6.3 million people suffer from Parkinson’s disease.
Parkinson incident rates increase with aging and the percentage of the world’s population above the age of 65 years will increase from 7% to 16% from 2000-2050 will serve this market as a driver.
- Track 17-1Neorocognitive Disorders
- Track 17-2Pathophysiology and Pharmacology
- Track 17-3Managing life with Parkinson’s disease
Cellular neuroscience is the investigation of neurons at a cell level. This incorporates morphology and physiological properties of single neurons. A few strategies, for example, intracellular recording, fix cinch, and voltage-brace method, pharmacology, confocal imaging, sub-atomic science, two photon laser checking microscopy and Ca2+ imaging have been utilized to study movement at the cell level. Cell neuroscience looks at the different sorts of neurons, the elements of various neurons, and the impact of neurons upon each other, how neurons cooperate.
Sub session in this track:
- Track 18-1Behavioural Neuroscience
- Track 18-2Neuroglial Cells
- Track 18-3Synaptic activities
- Track 18-4Neurotransmitters
- Track 18-5Synaptic Plasticity
- Track 18-6Neuromyelitis Optica
Epilepsy is a chronic disorder of the brain that affects people worldwide. It is characterized by recurrent seizures, which are brief episodes of involuntary movement that may involve a part of the body (partial) or the entire body (generalized), and is sometimes accompanied by loss of consciousness and control of bowel or bladder function. Approximately 50 million people worldwide suffer from epilepsy, now epilepsy becomes the most common neurological diseases globally. Nearly 80 percent people middle income countries who lives with epilepsy and do not get treatment they need. Peoples with epilepsy suffer discrimination in many parts of the world. Epilepsy results in an estimated annual cost of $15.5 billion.
The global epilepsy drug market is expected to grow at CAGR of 5% in the second half of the forecast period. In 2016, the global Epilepsy drug market is $4.3bn and is expected to grow at $6.9bn in 2027.
Epilepsy is one of the most common neurological disorders globally that affect approximately 50 million peoples worldwide.
On estimation 2.4 million peoples are diagnosed with epilepsy each year. Almost 80% peoples suffer from epilepsy lived in low and middle income countries.
The most common type of epilepsy is Idiopathic epilepsy which has no identifiable cause which affects 6 out of 10 people.
- Track 19-1Etiology and Epidemiology
- Track 19-2Epilepsy in Women and Inborn
- Track 19-3Epilepsy and Neuropsychology
- Track 19-4Epilepsia
- Track 19-5Cortical dysplasia and Epilepsy
- Track 19-6Impact of the Epilepsies on daily life
- Track 19-7Prevention and Management of Epilepsy